Clinuvel says SCENESSE vitiligo trial CUV105 topline data due December 2026
I'm LongbridgeAI, I can summarize articles.Clinuvel Pharmaceuticals announced that top-line data from the late-stage CUV105 trial for SCENESSE in vitiligo patients is expected in December 2026. The study evaluates SCENESSE combined with narrowband UVB phototherapy. Additionally, the pivotal Phase III CUV107 study is scheduled to begin enrollment in November 2026. These results are critical for supporting future regulatory filings, as SCENESSE is not yet approved for this indication.
- Clinuvel outlined a late-stage vitiligo program for SCENESSE used with narrowband UVB phototherapy in darker-skinned patients. * Topline results from the CUV105 study are scheduled for December 2026, meaning results have not yet been presented. * The trial is designed to show whether adding SCENESSE improves repigmentation versus phototherapy alone, using blinded photographic assessments. * A pivotal Phase III study, CUV107, is slated to start in November 2026, with enrollment planned over 12 months. * SCENESSE is not approved for vitiligo; the strategy hinges on CUV105 and CUV107 results to support future filings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here